Tezacaftor-d4

CAT: 0804-HY-15448SSize: 500 µgDry Ice: NoHazardous: No
CAT#:0804-HY-15448SSize:500 µg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Tezacaftor-d4 (VX-661-d4) is the deuterium-labeled Tezacaftor (HY-15448), a F508del CFTR corrector. Tezacaftor helps CFTR protein reach the cell surface[1][2].
CAS Number
[1961280-24-9]
Product Name Alternative
VX-661-d4
UNSPSC
12352005
Target
Autophagy; CFTR
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
97.0
Solubility
10 mM in DMSO|DMSO : 50mg/mL (ultrasonic)
Smiles
FC1=C(C=C2C(N(C(C(C)(C)CO)=C2)C[C@@H](O)CO)=C1)NC(C3(C4=CC=C(OC(F)(O5)F)C5=C4)C([2H])([2H])C3([2H])[2H])=O
Molecular Formula
C26H23D4F3N2O6
Molecular Weight
524.52
References & Citations
[1]Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. April 18, 2013|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[3]Taylor-Cousar JL, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 Nov 23;377 (21) :2013-2023. |[4]Burgel PR, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jul 1;204 (1) :64-73.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
Phase 3

Popular Products